Home > Boards > US Listed > Biotechs > Arena Pharmaceuticals, Inc. (ARNA)

orexigen is no compensation at this point whatsoever period.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
lovethatgreen Member Profile
Member Level 
Followed By 188
Posts 19,614
Boards Moderated 0
Alias Born 08/07/04
160x600 placeholder
Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 "PR Newswire (US)" - 7/25/2014 8:00:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 7/21/2014 4:33:20 PM
Arena Pharmaceuticals Enters into Marketing and Supply Agreement for BELVIQ® (lorcaserin HCl) in Israel "PR Newswire (US)" - 7/21/2014 8:00:00 AM
Arena Pharmaceuticals Issued Patent for APD371 by United States Patent and Trademark Office "PR Newswire (US)" - 7/15/2014 4:31:00 PM
Arena Pharmaceuticals Reports that Eisai Completes Planned Increase in Sales Force for BELVIQ® (lorcaserin HCl) CIV "PR Newswire (US)" - 7/10/2014 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 7/3/2014 4:38:31 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 6/27/2014 6:50:01 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 6/13/2014 5:23:37 PM
Arena Pharmaceuticals to Present at the 2014 Wells Fargo Securities Healthcare Conference "PR Newswire (US)" - 6/13/2014 8:00:00 AM
Lorcaserin HCl Data to be Presented at American Diabetes Association's 74th Scientific Sessions "PR Newswire (US)" - 6/9/2014 7:55:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 6/3/2014 8:15:29 AM
Arena Pharmaceuticals Initiates Phase 1b Clinical Trial of APD334 for Autoimmune Diseases "PR Newswire (US)" - 6/3/2014 8:00:00 AM
Arena Pharmaceuticals to Present at the Jefferies 2014 Global Healthcare Conference "PR Newswire (US)" - 5/27/2014 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 5/14/2014 7:34:50 PM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 5/12/2014 4:16:00 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 5/12/2014 4:11:21 PM
Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2014 Financial Results "PR Newswire (US)" - 5/12/2014 4:03:00 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 5/9/2014 12:09:58 PM
Arena Pharmaceuticals Reports that Eisai Plans to Further Increase its Sales Force for BELVIQ® (lorcaserin HCl) CIV by 50% "PR Newswire (US)" - 5/9/2014 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 5/7/2014 7:55:13 PM
Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Monday, May 12 "PR Newswire (US)" - 5/5/2014 8:00:00 AM
Additional Proxy Soliciting Materials (definitive) (defa14a) "Edgar (US Regulatory)" - 4/29/2014 3:13:17 PM
Proxy Statement (definitive) (def 14a) "Edgar (US Regulatory)" - 4/29/2014 3:11:15 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 4/24/2014 6:15:10 PM
Arena Pharmaceuticals Reports Eisai's Launch of National Television Advertising Campaign for BELVIQ® (lorcaserin HCl) CIV fo... "PR Newswire (US)" - 4/14/2014 8:33:00 AM
lovethatgreen Member Level  Monday, 05/14/12 08:57:20 AM
Re: gixxer11 post# 4348
Post # of 21524 
orexigen is no compensation at this point whatsoever period.

and vvus at the stage theyre at, is at a disadvantage in several ways

no manufacturing set up....the risks with the drug are numerous combined with detox requirements after 90 days

I could go on

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist